T‐Cell‐Targeted Immunofusion Proteins from E. coli
- 1 May 1996
- journal article
- conference paper
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 782 (1) , 544-554
- https://doi.org/10.1111/j.1749-6632.1996.tb40592.x
Abstract
Antibodies and antibody domains are ideal agents for targeting the surface of cells, and fusion proteins between cell-targeting domains and cytotoxic proteins may be particularly effective therapeutic reagents. We constructed a family of immunofusion proteins linking the humanized Fab, F(ab')2, or single-chain antibody form of the H65 antibody (which recognizes the CD5 antigen on the surface of human T cells) with the plant ribosome-inactivating protein gelonin. To maximize the product yield and simplify the production process, each fusion protein was linked to a bacterial signal sequence for expression in E. coli as a secreted protein. More than 30 fusion genes were assembled with antibody domains and gelonin in various physical orientations. Each immunofusion accumulated in the bacterial culture supernatant in a properly folded, active form. Bacteria transformed with each fusion gene were then grown in a fermentor, and product was recovered from the cell-free fermentation broth by column chromatography. All of the immunofusion proteins were purified by a single process and each was tested for cytotoxicity toward antigen-positive human cells. A compact cGMP fermentation area was built to manufacture these fusion proteins. Our integrated approach to microbial protein production, including molecular genetics, bacterial fermentation, and initial isolation, is described in detail.This publication has 25 references indexed in Scilit:
- Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugatesClinical and Experimental Immunology, 2008
- Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residuesProtein Engineering, Design and Selection, 1994
- Effects of administration of an anti‐cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studiesArthritis & Rheumatism, 1993
- High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody FragmentNature Biotechnology, 1992
- Renaturation, Purification and Characterization of Recombinant Fab-Fragments Produced in Escherichia coliNature Biotechnology, 1991
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989
- Escherichia coli Secretion of an Active Chimeric Antibody FragmentScience, 1988
- Assembly of a Functional Immunoglobulin F v Fragment in Escherichia coliScience, 1988
- High–Level Expression, Efficient Secretion and Folding of Human Growth Hormone in Escherichia coliBio/Technology, 1986
- High-level expression of M13 gene II protein from an inducible polycistronic messenger RNAGene, 1985